Dr. David Feifel is a neuropsychiatrist and neuroscientist. He is currently Professor Emeritus of Psychiatry, UC San Diego, School of Medicine and President of Kadima Neuropsychiatry Institute in La Jolla, California.
Dr. Feifel earned a B.Sc., M.A., M.D and a Ph.D. (Neurobiology) from the University of Toronto where he also completed an internship in Internal Medicine. He then completed a psychiatry residency at UC San Diego, serving as chief resident in his senior year. After residency, he was recruited to the faculty of UCSD’s Department of Psychiatry, subsequently rising to rank of full professor.
At UCSD, Dr. Feifel headed the Neuropsychiatry and Behavioral Medicine Program, established the UCSD Adult ADHD program, and founded the Center for Advanced Treatment of Mood and Anxiety Disorders (CATMAD), where he introduced several innovative treatments such as transcranial magnetic stimulation (TMS) and ketamine therapy. While at UCSD, Dr. Feifel also headed a, NIMH-funded, translational research program focusing on discovering new treatments for mental illness.
In 2017, Dr. Feifel established Kadima Neuropsychiatry Institute, which is devoted to developing and providing cutting edge treatments for neuropsychiatric disorders. Among the current projects at Kadima are phase II & III clinical trials of psilocybin (Compass Pathways), LSD (Minded) and 5-MeO-DMT (Beckley Psytech) and “Project Africa,” helping health officials in Rwanda establish advanced treatment clinics modeled after Kadima.
Addition distinctions include:
For more information on Kadima Neuropsychiatry Institute visit: https://www.kadimanp.com/